Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide for Diabetes Prevention in Obese Prediabetic Individuals
NCT02084654Phase 1Completed
- Sponsor
- Stanford University
- Start
- Nov 2007
- Primary completion
- Oct 2012
- Modality
- Peptides
01
Overview
Phase 1, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Stanford University. Primary endpoint: First-phase insulin response at 7 months. Started Nov 2007; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02084654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02084654.